<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161118</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-3903</org_study_id>
    <nct_id>NCT04161118</nct_id>
  </id_info>
  <brief_title>TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma</brief_title>
  <acronym>TIGER-CTL019</acronym>
  <official_title>Phase II Trial of TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II trial of TisaGenlecleucel (CTL019) in Elderly Patients with First-Relapsed or&#xD;
      Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, prospective, multicenter phase-II trial for elderly patients with aNHL&#xD;
      failing 1st-line treatment with immunochemotherapy containing rituximab and anthracycline,&#xD;
      who are not eligible for either autologous or allogeneic stem cell transplantation, defined&#xD;
      as age &gt; 65 years, or &gt; 60 years old with HCT-CI score &gt;2. This trial evaluates the CMR rate&#xD;
      12 weeks after tisagenlecleucel (CTL019) infusion, the incidence and severity of adverse&#xD;
      events, progression-free survival, and overall survival after one and two years after&#xD;
      tisagenlecleucel (CTL019).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of the efficacy of treatment with tisagenlecleucel (CTL019) in elderly patients with r/r aNHL by measuring the complete metabolic response (CMR) rate 12 weeks after tisagenlecleucel (CTL019) infusion</measure>
    <time_frame>12 weeks after tisagenlecleucel (CTL019) infusion</time_frame>
    <description>Estimation of the efficacy of treatment with tisagenlecleucel (CTL019) in elderly patients with r/r aNHL by measuring the complete metabolic response (CMR) rate 12 weeks after tisagenlecleucel (CTL019) infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>From study start to study end (44 months)</time_frame>
    <description>Incidence and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) rates at 1 and 2 year(s)</measure>
    <time_frame>Up to two years from study start</time_frame>
    <description>Progression-free survival (PFS) rates at 1 and 2 year(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rates at 1 and 2 year(s)</measure>
    <time_frame>Up to two years from study start</time_frame>
    <description>Overall survival (OS) rates at 1 and 2 year(s)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tisagenlecleucel (CTL019)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a single target dose of 0.6 to 6.0 × 108 of autologous tisagenlecleucel (CTL019) transduced T-cells with a viability of at least 70% administered via IV infusion after optional bridging with chemo- or immunotherapy and lymphodepleting (LD) chemotherapy with cyclophosphamide and fludarabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTL019</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>Tisagenlecleucel (CTL019)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written, signed and dated informed consent must be obtained prior to participation in&#xD;
             the study&#xD;
&#xD;
          2. Patients with first relapse of aggressive B-cell Non-Hodgkin Lymphoma (aNHL) within&#xD;
             365 days after rituximab- and anthracycline-containing first-line immunochemotherapy&#xD;
             or aNHL refractory to first-line therapy (not achieving a CR or PR), who are&#xD;
             ineligible for either autologous or allogeneic stem cell transplantation, defined by&#xD;
             age &gt; 65 years, or &gt; 60 years with a HCT-CI score &gt; 2&#xD;
             (https://qxmd.com/calculate/calculator_108/hematopoietic-cell-transplantation-specific&#xD;
             -comorbidity-index-hct-ci) and not older than 80 years.&#xD;
&#xD;
          3. Histologically confirmed (by local histopathological assessment) aNHL at relapse or&#xD;
             progression due to refractory disease after front line therapy. aNHL is defined by the&#xD;
             following list of subtypes:&#xD;
&#xD;
               1. DLBCL, NOS (GCB, ABC, centroblastic, immunoblastic, anaplastic)&#xD;
&#xD;
               2. FL grade 3B&#xD;
&#xD;
               3. T-cell-rich/histiocyte-rich large B-cell lymphoma (T/HRBCL)&#xD;
&#xD;
               4. DLBCL associated with chronic inflammation&#xD;
&#xD;
               5. Intravascular large B-cell lymphoma&#xD;
&#xD;
               6. ALK+ large B-cell lymphoma&#xD;
&#xD;
               7. B-cell lymphoma, unclassifiable, (with features intermediate between DLBCL and&#xD;
                  classical HL)&#xD;
&#xD;
               8. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements&#xD;
&#xD;
               9. High-grade B-cell lymphoma, NOS&#xD;
&#xD;
              10. HHV8+ DLBCL, NOS&#xD;
&#xD;
              11. DLBCL transformed from follicular lymphoma&#xD;
&#xD;
              12. DLBCL transformed from marginal zone lymphoma&#xD;
&#xD;
              13. DLBCL, leg type&#xD;
&#xD;
          4. Measurable disease:&#xD;
&#xD;
               1. Nodal lesions &gt;15 mm in the long axis, regardless of the length of the short&#xD;
                  axis, and/or&#xD;
&#xD;
               2. Extranodal lesions (outside lymph node or nodal mass, but including liver and&#xD;
                  spleen) &gt;10 mm in long AND short axis&#xD;
&#xD;
          5. ECOG performance status 0-2&#xD;
&#xD;
          6. Adequate organ function:&#xD;
&#xD;
             a. Kidney function defined as: i. Serum creatinine estimated glomerular filtration&#xD;
             rate GFR ≥ 30mL/min b. Hepatic function defined as: i. ALT and AST ≤ 5 × ULN, except&#xD;
             for aNHL-related functional impairment. ii. Bilirubin ≤2.0 mg/dl except for patients&#xD;
             with Gilbert syndrome, who may be included if their total bilirubin is ≤3.0 × ULN and&#xD;
             direct bilirubin ≤1.5 × ULN OR for aNHL-related functional impairment c. Adequate bone&#xD;
             marrow function (regardless of transfusion) defined as: i. WBC ≥2500/µL ii. Absolute&#xD;
             neutrophil count (ANC) &gt;1000/µL iii. Platelets ≥50,000/µL iv. Hemoglobin &gt;8.0 g/dl d.&#xD;
             Minimum level of pulmonary function defined as: i. No or mild dyspnea (≤ Grade 1) ii.&#xD;
             pulse oxygenation ≥ 91% on room air&#xD;
&#xD;
          7. Life expectancy of more than six months&#xD;
&#xD;
          8. Women have to be in menopausal or post-menopausal status or confirmed as not having&#xD;
             potential on childbearing&#xD;
&#xD;
          9. Male participants with female partners of childbearing potential are eligible to&#xD;
             participate if they agree to contraceptive methods as described in the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with Richter's transformation, Burkitt lymphoma, or primary CNS lymphoma&#xD;
             (PCNSL)&#xD;
&#xD;
          2. Prior treatment with anti-CD19 therapy, adoptive T-cell therapy, or any prior gene&#xD;
             therapy product&#xD;
&#xD;
          3. Treatment with any lymphoma-directed second-line anticancer therapy prior to&#xD;
             enrollment with the exception of intermittent steroid therapy. After enrollment,&#xD;
             bridging therapy is permitted for disease control.&#xD;
&#xD;
          4. Patients with active CNS involvement are excluded, except if the CNS involvement has&#xD;
             been effectively treated (i.e. patient is asymptomatic) and local treatment was &gt;4&#xD;
             weeks before enrollment&#xD;
&#xD;
          5. Prior allogeneic bone marrow transplantation (HSCT)&#xD;
&#xD;
          6. Active hepatitis B, hepatitis C, or hepatitis E infection&#xD;
&#xD;
          7. HIV-positive patients&#xD;
&#xD;
          8. Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood&#xD;
             culture positive ≤ 72 hours prior to infusion)&#xD;
&#xD;
          9. Any of the following cardiovascular conditions:&#xD;
&#xD;
               1. Unstable angina, myocardial infarction, coronary artery bypass graft (CABG), or&#xD;
                  stroke within 6 months prior to screening,&#xD;
&#xD;
               2. LVEF &lt;45% as determined by ECHO at screening except for aNHL-related functional&#xD;
                  impairment,&#xD;
&#xD;
               3. NYHA functional class III or IV (Chavey et al. 2001) at screening,&#xD;
&#xD;
               4. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia),&#xD;
                  complete left bundle branch block, high-grade AV block (e.g., bifascicular block,&#xD;
                  Mobitz type II) and third degree AV block, unless adequately controlled by&#xD;
                  pacemaker implantation,&#xD;
&#xD;
               5. Resting QTcF ≥450 msec (male) or ≥460 msec (female) at screening or inability to&#xD;
                  determine the QTcF interval,&#xD;
&#xD;
               6. Risk factors for Torsades de Point (TdP), including uncorrected hypokalemia or&#xD;
                  hypomagnesemia, history of cardiac failure, or history of clinically&#xD;
                  significant/symptomatic bradycardia, or any of the following:&#xD;
&#xD;
               7. Long QT syndrome, family history of idiopathic sudden death or congenital long QT&#xD;
                  syndrome, or&#xD;
&#xD;
               8. Concomitant medication(s) with a &quot;Known Risk of Torsades de Point&quot; per&#xD;
                  www.qtdrugs.org that cannot be discontinued or replaced by safe alternative&#xD;
                  medication.&#xD;
&#xD;
         10. Previous or concurrent malignancy with the following exceptions:&#xD;
&#xD;
               1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing&#xD;
                  is required prior to study entry)&#xD;
&#xD;
               2. In situ carcinoma of the cervix or breast, treated curatively and without&#xD;
                  evidence of recurrence for at least 3 years prior to the study&#xD;
&#xD;
               3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               4. Adequately treated carcinoma in situ without evidence of of recurrence for at&#xD;
                  least 3 years prior to the study&#xD;
&#xD;
               5. A primary malignancy which has been completely resected and in complete remission&#xD;
                  for ≥ 3 years&#xD;
&#xD;
         11. Pregnant or nursing (lactating) women and women who are not confirmed to be&#xD;
             menopausal/post-menopausal. Or women who are capable of giving birth.&#xD;
&#xD;
         12. Intolerance to the excipients of the tisagenlecleucel cell product&#xD;
&#xD;
         13. Active or history of inflammatory disorders or autoimmune disease that required&#xD;
             systemic steroids or immunosuppressive medications, with exception of vitiligo or&#xD;
             resolved childhood asthma&#xD;
&#xD;
         14. Active tuberculosis&#xD;
&#xD;
         15. Exposure to any investigational agent(s) within 4 weeks prior to study entry&#xD;
&#xD;
         16. Chemotherapy less than 2 weeks before leukapheresis&#xD;
&#xD;
         17. Simultaneous radiotherapy to tisagenlecleucel infusion (radiotherapy between&#xD;
             leukapheresis and day -6 before tisagenlecleucel infusion is permitted)&#xD;
&#xD;
         18. Ongoing necessity for systemic corticosteroids &gt;10mg daily prednisone equivalent.&#xD;
             Inhaled or topical steroids and adrenal replacement steroid doses &gt; 10 mg daily&#xD;
             prednisone equivalent are permitted in the absence of active autoimmune disease.&#xD;
&#xD;
         19. History of active primary immunodeficiency&#xD;
&#xD;
         20. Major surgery (defined as opening at least one body cavity) within 4 weeks prior to&#xD;
             study entry&#xD;
&#xD;
         21. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic&#xD;
             pneumonitis, or evidence of active pneumonitis on screening CT scan&#xD;
&#xD;
         22. Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2,&#xD;
             anti-CTLA-4 antibodies, other immune checkpoint inhibitors&#xD;
&#xD;
         23. Prior treatment with any anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy.&#xD;
&#xD;
         24. Current treatment within another therapeutic clinical trial with experimental and not&#xD;
             approved drugs and treatment combinations&#xD;
&#xD;
         25. Patient's lack of accountability and inability to appreciate the nature, meaning and&#xD;
             consequences of the trial and to formulate his/her own wishes correspondingly&#xD;
&#xD;
         26. Non-compliance, e.g. due to&#xD;
&#xD;
               1. Drug dependency or substance abuse that would interfere with cooperation with&#xD;
                  requirements of the trial&#xD;
&#xD;
               2. Refusal of blood products during treatment&#xD;
&#xD;
               3. Change of residence to abroad&#xD;
&#xD;
               4. any similar circumstances that appear to make protocol treatment or long-term&#xD;
                  follow-up impossible&#xD;
&#xD;
         27. Patients who have a relationship of dependence or employer-employee relationship to&#xD;
             the sponsor or the investigator&#xD;
&#xD;
         28. Committal to an institution on judicial or official order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Borchmann, Prof. Dr. med.</last_name>
    <phone>+49 221 478</phone>
    <phone_ext>88180</phone_ext>
    <email>Tiger_Studienteam@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anja Juehling, Dr. med.</last_name>
    <phone>+49 221 478</phone>
    <phone_ext>30949</phone_ext>
    <email>Tiger_Studienteam@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Borchmann, Prof. Dr. med.</last_name>
      <phone>+49 221 478</phone>
      <phone_ext>88180</phone_ext>
      <email>Tiger_Studienteam@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Anja Juehling, Dr. med.</last_name>
      <phone>+49 221 478</phone>
      <phone_ext>30949</phone_ext>
      <email>Tiger_Studienteam@uk-koeln.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Essen, Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bastian Von Tresckow, PD Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Andreas Hüttmann, PD Dr. med.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Peter Borchmann</investigator_full_name>
    <investigator_title>Trial Chairman</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

